Efficacy and Safety of Taitacept in Treatment of Refractory or Recurrent Anti-NMDAR/anti-LGI1 Encephalitis
Efficacy and Safety of Taitacept in Treatment of Refractory or Recurrent Anti-NMDAR/anti-LGI1 Encephalitis
Recruiting · NCT06510283 · Registry updated 2024-11-20Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Taitacept in Treatment of Refractory or Recurrent Anti-NMDAR/anti-LGI1 Encephalitis | Neoplasms by Site, Neuroinflammatory Diseases, Paraneoplastic Syndromes, Nervous System, anti-NMDA receptor encephalitis, autoimmune disease, autoimmune disorder of the nervous system, brain disorder, central nervous system disorder, encephalitis, immune system disorder, neoplasm, nervous system disorder, neurodegenerative disease, paraneoplastic syndrome | Recruiting | Phase 2 | 2024-11-20 | NCT06510283 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Beijing Tongren Hospital | 60 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beijing Tongren Hospital,Capital Medical University | Beijing | China | 1 |